Compare Sun Pharma with Lupin - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs LUPIN - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA LUPIN SUN PHARMA/
LUPIN
 
P/E (TTM) x 31.9 25.3 125.9% View Chart
P/BV x 4.2 3.1 135.6% View Chart
Dividend Yield % 0.9 0.7 131.9%  

Financials

 SUN PHARMA   LUPIN
EQUITY SHARE DATA
    SUN PHARMA
Mar-21
LUPIN
Mar-21
SUN PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs6541,122 58.3%   
Low Rs339576 58.8%   
Sales per share (Unadj.) Rs139.6334.2 41.8%  
Earnings per share (Unadj.) Rs9.527.0 35.2%  
Cash flow per share (Unadj.) Rs18.246.6 39.0%  
Dividends per share (Unadj.) Rs7.506.50 115.4%  
Avg Dividend yield %1.50.8 197.4%  
Book value per share (Unadj.) Rs193.6300.1 64.5%  
Shares outstanding (eoy) m2,399.34453.68 528.9%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x3.62.5 139.9%   
Avg P/E ratio x52.131.4 166.0%  
P/CF ratio (eoy) x27.318.2 149.7%  
Price / Book Value ratio x2.62.8 90.6%  
Dividend payout %78.824.0 327.6%   
Avg Mkt Cap Rs m1,190,430385,072 309.1%   
No. of employees `000NANA-   
Total wages/salary Rs m68,62228,259 242.8%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m334,981151,630 220.9%  
Other income Rs m8,5921,363 630.4%   
Total revenues Rs m343,573152,993 224.6%   
Gross profit Rs m41,61625,669 162.1%  
Depreciation Rs m20,8008,874 234.4%   
Interest Rs m1,4141,406 100.6%   
Profit before tax Rs m27,99416,751 167.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,1474,485 114.8%   
Profit after tax Rs m22,84712,266 186.3%  
Gross profit margin %12.416.9 73.4%  
Effective tax rate %18.426.8 68.7%   
Net profit margin %6.88.1 84.3%  
BALANCE SHEET DATA
Current assets Rs m304,421139,864 217.7%   
Current liabilities Rs m161,45684,361 191.4%   
Net working cap to sales %42.736.6 116.6%  
Current ratio x1.91.7 113.7%  
Inventory Days Days14969 215.5%  
Debtors Days Days99108 91.7%  
Net fixed assets Rs m336,68294,439 356.5%   
Share capital Rs m2,399907 264.4%   
"Free" reserves Rs m462,229135,229 341.8%   
Net worth Rs m464,628136,136 341.3%   
Long term debt Rs m8,981161 5,571.5%   
Total assets Rs m641,103234,302 273.6%  
Interest coverage x20.812.9 161.1%   
Debt to equity ratio x00 1,632.5%  
Sales to assets ratio x0.50.6 80.7%   
Return on assets %3.85.8 64.9%  
Return on equity %4.99.0 54.6%  
Return on capital %6.213.3 46.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m84,49351,027 165.6%   
Fx outflow Rs m30,33421,081 143.9%   
Net fx Rs m54,15929,946 180.9%   
CASH FLOW
From Operations Rs m61,70418,218 338.7%  
From Investments Rs m5,362-12,396 -43.3%  
From Financial Activity Rs m-59,805-18,853 317.2%  
Net Cashflow Rs m5,964-13,031 -45.8%  

Share Holding

Indian Promoters % 54.5 46.5 117.1%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 33.8 40.4 83.6%  
FIIs % 12.1 15.7 77.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 45.5 53.2 85.6%  
Shareholders   675,908 361,288 187.1%  
Pledged promoter(s) holding % 6.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   PARNAX LAB  MAKERS LAB.  GLENMARK LIFE SCIENCES  SANDU PHARMA  NATCO PHARMA  



Today's Market

Sensex Ends 383 Points Higher; Metal and Realty Stocks Rally(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended higher.

Related Views on News

SUN PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Oct 22, 2021 | Updated on Oct 22, 2021

Here's an analysis of the annual report of SUN PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

LUPIN 2020-21 Annual Report Analysis (Annual Result Update)

Oct 19, 2021 | Updated on Oct 19, 2021

Here's an analysis of the annual report of LUPIN for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

More Views on News

Most Popular

5 Green Energy Stocks to Watch as India Readies for a Revolution(Views On News)

Oct 13, 2021

The excitement around green energy stocks has opened up a huge contrarian opportunity in the traditional energy space.

Could HDFC Bank be a Big EV Winner? The Answer Will Surprise You...(Profit Hunter)

Oct 13, 2021

Why should investors take it for granted that India's Tesla will be one of the major auto stocks?

Tata Group Stocks are on Fire: Which one Should You Buy?(Profit Hunter)

Oct 15, 2021

Tata group stocks are on fire. Find out which one deserves your attention.

Massive Surge in the Shares of Tata Motors Today. Key Factors Favouring the Rally(Views On News)

Oct 13, 2021

Tata Motors zooms 23% after report of TPG investing Rs 75 bn in EV arm.

India's Big PSU Selloff: Watch Out for these Top Stocks(Views On News)

Oct 15, 2021

The government's plan to divest its stakes in PSUs could spark off a rally in these four stocks.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Oct 26, 2021 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS